Literature DB >> 31092411

Medications associated with fracture risk in patients with rheumatoid arthritis.

Gulsen Ozen1, Sofia Pedro2, Frederick Wolfe2, Kaleb Michaud3,2.   

Abstract

OBJECTIVE: To examine the fracture risk with use of disease-modifying antirheumatic drugs (DMARDs), statins, proton pump inhibitors (PPIs), opioids, non-opioid analgesics and psychotropic medications in a US-wide observational rheumatoid arthritis (RA) cohort.
METHODS: Patients with RA without prior fracture from 2001 through 2017 in FORWARD, a longitudinal observational registry, were assessed for osteoporosis-related site fractures (vertebra, hip, forearm and humerus). DMARD exposure was assessed in four mutually exclusive groups: (1) methotrexate monotherapy-reference, (2) tumour necrosis factor-α inhibitors (TNFi), (3) non-TNFi biologics and (4) others. Non-DMARDs and glucocorticoids were classified as current/ever use and based on treatment duration. Fracture Risk Assessment Tool (FRAX) scores estimating for 10-year major osteoporotic fractures were calculated. Cox proportional hazard models stratified by FRAX were used to adjust for confounders.
RESULTS: During median (IQR) 3.0 (1.5-6.0) years of follow-up in 11 412 patients, 914 fractures were observed. The adjusted models showed a significant fracture risk increase with use of any dose glucocorticoids ≥3 months (HR (95% CI) for <7.5 mg/day 1.26 (1.07 to 1.48) and for ≥7.5 mg/day 1.57 (1.27 to 1.94)), opioids (for weak: 1.37 (1.18 to 1.59); strong: 1.53 (1.24 to 1.88)) and selective serotonin reuptake inhibitors (SSRIs) (1.37 (1.15 to 1.63)). Fracture risk with opioids increased within 1 month of use (1.66 (1.36 to 2.04)) and with SSRIs >3 months of use (1.25 (1.01 to 1.55)). Statins (0.77 (0.62 to 0.96)) and TNFi (0.72 (0.54 to 0.97)) were associated with reduction in vertebral fracture risk only. PPIs and other psychotropic medications were not associated with increased fracture risk.
CONCLUSION: Use of opioids, SSRIs and glucocorticoids were associated with increased risk of any fracture in patients with RA, whereas statins and TNFi were associated with decreased vertebral fractures. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  antidepressants; cohort study; fracture; opioids; rheumatoid arthritis; statins

Mesh:

Substances:

Year:  2019        PMID: 31092411     DOI: 10.1136/annrheumdis-2019-215328

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  24 in total

1.  Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study.

Authors:  N Guañabens; J M Olmos; J L Hernández; D Cerdà; C Hidalgo Calleja; J A Martinez López; L Arboleya; F J Aguilar Del Rey; S Martinez Pardo; I Ros Vilamajó; X Suris Armangué; D Grados; C Beltrán Audera; E Suero-Rosario; I Gómez Gracia; A Salmoral Chamizo; I Martín-Esteve; H Florez; A Naranjo; S Castañeda; S Ojeda Bruno; S García Carazo; A García Vadillo; L López Vives; À Martínez-Ferrer; H Borrell Paños; P Aguado Acín; R Castellanos-Moreira; C Tebé; C Gómez-Vaquero
Journal:  Osteoporos Int       Date:  2021-01-18       Impact factor: 4.507

2.  Incidence and risk factors for vertebral fracture in rheumatoid arthritis: an update meta-analysis.

Authors:  Yang Liu; Jun Jiang; Minmin Mo; Xiaohong Sun; Kailong Yu
Journal:  Clin Rheumatol       Date:  2022-01-10       Impact factor: 2.980

3.  Impact of continuity of care on risk for major osteoporotic fracture in patients with new onset rheumatoid arthritis.

Authors:  Seung Hoon Kim; Hyunkyu Kim; Sung Hoon Jeong; Suk-Yong Jang; Eun-Cheol Park
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

Review 4.  Methotrexate osteopathy: five cases and systematic literature review.

Authors:  F Robin; S Cadiou; J-D Albert; G Bart; G Coiffier; P Guggenbuhl
Journal:  Osteoporos Int       Date:  2020-10-30       Impact factor: 4.507

Review 5.  Review of publications evaluating opioid use in patients with inflammatory rheumatic disease.

Authors:  Christine Anastasiou; Jinoos Yazdany
Journal:  Curr Opin Rheumatol       Date:  2022-03-01       Impact factor: 5.006

Review 6.  A General Introduction to Glucocorticoid Biology.

Authors:  Steven Timmermans; Jolien Souffriau; Claude Libert
Journal:  Front Immunol       Date:  2019-07-04       Impact factor: 7.561

Review 7.  Osteoporosis in Rheumatic Diseases.

Authors:  Giovanni Adami; Angelo Fassio; Maurizio Rossini; Cristian Caimmi; Alessandro Giollo; Giovanni Orsolini; Ombretta Viapiana; Davide Gatti
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

8.  Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children.

Authors:  Yun-Han Wang; Viktor Wintzell; Jonas F Ludvigsson; Henrik Svanström; Björn Pasternak
Journal:  JAMA Pediatr       Date:  2020-06-01       Impact factor: 16.193

9.  Therapeutic effect of various ginsenosides on rheumatoid arthritis.

Authors:  Meng Zhang; Hongwei Ren; Kun Li; Shengsheng Xie; Ru Zhang; Longlong Zhang; Jiaxuan Xia; Xing Chen; Xilin Li; Jianxin Wang
Journal:  BMC Complement Med Ther       Date:  2021-05-25

Review 10.  Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide.

Authors:  Hennie G Raterman; Willem F Lems
Journal:  Drugs Aging       Date:  2019-12       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.